• Explore /
  • Poster
  • / Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).

Matching-adjusted indirect treatment comparison (MAIC) of teclistamab (tec) versus belantamab mafodotin (belamaf) for the treatment of patients (pts) with triple-class exposed (TCE), relapsed/refractory multiple myeloma (RRMM).

Abstract Video & Slides Poster

Authors

null

Philippe Moreau

Hematology Clinic, University Hospital Hôtel-Dieu, Nantes, France

Philippe Moreau , Saad Zafar Usmani , Niels W.C.J. van de Donk , Alfred L. Garfall , Michel Delforge , Albert Oriol Rocafiguera , Ajay K. Nooka , Laura Rosiñol , Nizar J. Bahlis , Paula Rodríguez-Otero , Thomas G. Martin , Joris Diels , Suzy Van Sanden , Lixia Pei , Eric Ammann , Rachel Kobos , Mary Slavcev , Jennifer Smit , Anil Londhe , Amrita Y. Krishnan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Plasma Cell Dyscrasia

Track

Hematologic Malignancies

Sub Track

Multiple Myeloma

Clinical Trial Registration Number

NCT04557098; NCT03525678

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 8035)

DOI

10.1200/JCO.2022.40.16_suppl.8035

Abstract #

8035

Poster Bd #

459

Abstract Disclosures

Similar Posters

First Author: Niels W.C.J. van de Donk

First Author: Saad Zafar Usmani

First Author: Maria-Victoria Mateos

First Author: Robert M. Rifkin